» Articles » PMID: 35637215

Inhibiting Multiple Forms of Cell Death Optimizes Ganglion Cells Survival After Retinal Ischemia Reperfusion Injury

Overview
Journal Cell Death Dis
Date 2022 May 31
PMID 35637215
Authors
Affiliations
Soon will be listed here.
Abstract

Progressive retinal ganglion cells (RGCs) death that triggered by retinal ischemia reperfusion (IR), leads to irreversible visual impairment and blindness, but our knowledge of post-IR neuronal death and related mechanisms is limited. In this study, we first demonstrated that apart from necroptosis, which occurs before apoptosis, ferroptosis, which is characterized by iron deposition and lipid peroxidation, is involved in the whole course of retinal IR in mice. Correspondingly, all three types of RGCs death were found in retina samples from human glaucoma donors. Further, inhibitors of apoptosis, necroptosis, and ferroptosis (z-VAD-FMK, Necrostatin-1, and Ferrostatin-1, respectively) all exhibited marked RGC protection against IR both in mice and primary cultured RGCs, with Ferrostatin-1 conferring the best therapeutic effect, suggesting ferroptosis plays a more prominent role in the process of RGC death. We also found that activated microglia, Müller cells, immune responses, and intracellular reactive oxygen species accumulation following IR were significantly mitigated after each inhibitor treatment, albeit to varying degrees. Moreover, Ferrostatin-1 in combination with z-VAD-FMK and Necrostatin-1 prevented IR-induced RGC death better than any inhibitor alone. These findings stand to advance our knowledge of the post-IR RGC death cascade and guide future therapy for RGC protection.

Citing Articles

O-GlcNAcylation attenuates ischemia-reperfusion-induced pulmonary epithelial cell ferroptosis via the Nrf2/G6PDH pathway.

Yang L, Tang H, Wang J, Xu D, Xuan R, Xie S BMC Biol. 2025; 23(1):32.

PMID: 39901237 PMC: 11792224. DOI: 10.1186/s12915-025-02126-w.


Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model.

Tu X, Zou Z, Li J, Zeng S, Luo Z, Li G Chin Med J (Engl). 2024; 138(2):172-184.

PMID: 39719694 PMC: 11745860. DOI: 10.1097/CM9.0000000000003387.


Targeting ferroptosis: a novel therapeutic strategy for the treatment of retinal diseases.

Hao X, Xu W, Zhang X, Xue J Front Pharmacol. 2024; 15:1489877.

PMID: 39539617 PMC: 11557320. DOI: 10.3389/fphar.2024.1489877.


Ion channel Piezo1 induces ferroptosis of trabecular meshwork cells: a novel observation in the pathogenesis in primary open angle glaucoma.

Liu K, Xu J, Yang R, Wang F, Su Y Am J Physiol Cell Physiol. 2024; 327(6):C1591-C1603.

PMID: 39466179 PMC: 11684867. DOI: 10.1152/ajpcell.00173.2024.


Roflumilast Attenuates Microglial Senescence and Retinal Inflammatory Neurodegeneration Post Retinal Ischemia Reperfusion Injury Through Inhibiting NLRP3 Inflammasome.

Ou C, Lin Y, Wen J, Zhang H, Xu Y, Zhang N Invest Ophthalmol Vis Sci. 2024; 65(12):38.

PMID: 39446353 PMC: 11512574. DOI: 10.1167/iovs.65.12.38.


References
1.
Zaninello M, Scorrano L . Rapidly purified ganglion cells from neonatal mouse retinas allow studies of mitochondrial morphology and autophagy. Pharmacol Res. 2018; 138:16-24. DOI: 10.1016/j.phrs.2018.07.024. View

2.
Villalpando-Rodriguez G, Gibson S . Reactive Oxygen Species (ROS) Regulates Different Types of Cell Death by Acting as a Rheostat. Oxid Med Cell Longev. 2021; 2021:9912436. PMC: 8380163. DOI: 10.1155/2021/9912436. View

3.
Chen H, Deng Y, Gan X, Li Y, Huang W, Lu L . NLRP12 collaborates with NLRP3 and NLRC4 to promote pyroptosis inducing ganglion cell death of acute glaucoma. Mol Neurodegener. 2020; 15(1):26. PMC: 7161290. DOI: 10.1186/s13024-020-00372-w. View

4.
Doll S, Porto Freitas F, Shah R, Aldrovandi M, Costa Da Silva M, Ingold I . FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019; 575(7784):693-698. DOI: 10.1038/s41586-019-1707-0. View

5.
Li W, Yang C, Lu J, Huang P, Barnstable C, Zhang C . Tetrandrine protects mouse retinal ganglion cells from ischemic injury. Drug Des Devel Ther. 2014; 8:327-39. PMC: 3968085. DOI: 10.2147/DDDT.S55407. View